Medicare Part D enrollees without low-income subsidies saw their insulin costs cut in half between 2020 and 2024, with average out-of-pocket spending per prescription dropping from $54 to $25, KFF reported.
The decline tracks the rollout of two overlapping federal policies: a voluntary Trump-era model that began capping copays at $35 for select insulins in 2021, followed by the Inflation Reduction Act’s mandatory $35 cap applied to all covered insulin products in 2023.
Aggregate spending by this group fell from $971 million to $506 million over the five-year span, even as the number of insulin users rose from 1.7 million to 1.9 million and total prescriptions increased from 18.1 million to 20.4 million.
“The implementation of these voluntary and mandatory measures to improve the affordability of insulin for Medicare Part D enrollees resulted in a substantial reduction in out-of-pocket spending,” the KFF analysis concluded. The research, supported by Arnold Ventures, examined Medicare Part D prescription drug event data for enrollees without Low-Income Subsidies (LIS), who face the full brunt of cost-sharing.
Per-prescription costs fell 26 percent in 2021, the first year of the voluntary Part D Senior Savings Model, dropping from $54 to $40. After a modest dip to $36 in 2022, the mandatory IRA cap drove a further 28 percent reduction to $26 in 2023, settling at $25 in 2024. For enrollees filling the typical 11 prescriptions annually, that translated to a 54 percent cut in yearly out-of-pocket burden, from $572 to $265.
Medicare Part D Caps Insulin Copays at $35 Monthly
- If you have Medicare Part D and do not qualify for Extra Help, your maximum monthly copay for any covered insulin is now $35, regardless of the brand or type you use.
- This cap applies automatically at the pharmacy counter; you do not need to enroll in a special program or switch plans to receive it.
- The savings are sustained: average costs per prescription have stabilized around $25, well below the statutory ceiling.
Policy Mechanics Drove the Drop
The Part D Senior Savings Model, launched by the Centers for Medicare & Medicaid Services (CMS) Innovation Center in 2021, relied on participating plans voluntarily limiting copays for selected insulin formulations to $35. Participation was uneven; not all plans joined, and covered products varied.
The Inflation Reduction Act, signed in August 2022, replaced that patchwork with a uniform mandate effective January 2023: every Part D plan must cap beneficiary cost-sharing for all covered insulin products at $35 per month’s supply.
The mandate also extended to insulin furnished under Part B—typically insulin used with durable medical equipment like pumps—effective July 2023. KFF’s analysis focused on Part D data, capturing the bulk of outpatient insulin claims.
Product-Level Prices Converge Below the Cap
In 2020, the ten most commonly used insulin products all carried average out-of-pocket costs above $35 for a 30-day supply, ranging from $43 for Insulin Lispro Kwikpen U-100 to $70 for Tresiba Flextouch U-200. By 2024, every one of those products averaged below the $35 threshold. Basaglar Kwikpen U-100 topped the list at $29, while Lantus Solostar sat at $23.
The convergence reflects the IRA’s design: the $35 cap is a ceiling, not a floor. Plans negotiate prices with manufacturers, and beneficiary cost-sharing cannot exceed the statutory limit. The analysis noted that per-capita insulin use remained flat at roughly 11 fills per user per year, suggesting the aggregate prescription growth stems from overall Part D enrollment gains rather than clinical escalation.
Low-Income Subsidy Enrollees Saw Minimal Change
Beneficiaries receiving the Part D Low-Income Subsidy (LIS)—who pay only nominal copays—were excluded from the primary cost analysis. Including them, total Medicare out-of-pocket insulin spending fell from just over $1.0 billion in 2020 to $535 million in 2024. The modest difference between the LIS-inclusive and LIS-exclusive totals shows that the policy’s financial relief is concentrated among the roughly 1.9 million non-LIS users.
Analysis Addresses Insurance Benefits Not Clinical Therapy
This analysis concerns insurance benefit design, not clinical therapy.
The Private Insurance Gap Remains
Legislation to extend the $35 copay cap to commercially insured patients has been introduced in Congress but not enacted. Several states have implemented their own caps for state-regulated plans, though self-funded employer plans—covering roughly 65 percent of privately insured workers—are preempted by federal ERISA law and unaffected by state mandates.
KFF previously estimated that privately insured patients with diabetes face average annual out-of-pocket insulin costs exceeding hundreds of dollars, with some paying over a thousand dollars.
KFF, founded in 1948 as the Kaiser Family Foundation by industrialist Henry J. Kaiser, became fully independent of Kaiser Permanente and Kaiser Industries by 1985. Since 1990, under CEO Drew Altman, it transformed from a grant-making foundation into an operating organization that conducts its own policy research, polling, and journalism, including KFF Health News, whose reporters were Pulitzer finalists in 2020 and 2024. The IRS reclassified it as a public charity in 2019.
The KFF analysis, conducted by Juliette Cubanski, Meredith Freed, and independent consultant Anthony Damico, maintains full editorial control over its policy work. Data sourced from CMS Part D prescription drug event files.
References
- Cubanski J, Freed M, Damico A. Out-of-Pocket Costs for Insulin Among People with Medicare Decreased by Half Between 2020 and 2024. KFF. Published November 2026.
- Centers for Medicare & Medicaid Services. Medicare Part D Senior Savings Model. CMS Innovation Center.
- Inflation Reduction Act of 2022, Pub. L. 117-169, Sec. 11403 (insulin cost-sharing cap).
- American Diabetes Association. Insulin Access and Affordability Working Group: Conclusions and Recommendations. Diabetes Care. 2018;41(6):1299-1311.
- Luo J, et al. Trends in Insulin Out-of-Pocket Costs for Privately Insured and Medicare Beneficiaries. JAMA. 2022;327(12):1175-1177.
Worth a look
- Guinea Declares Mpox Epidemic Over After 2,395 Cases and Six Deaths
- MHRA Updates Gene Therapy Rules, Launches AI Manufacturing Support; FDA Expands Quality Testing, Global Data Sharing
- Manchester United Managerial Costs Near £100m, Club Filing Says (time.news)
- Inflation Since October 2024 Adds About $4,720 a Year to Household Costs (daybreakwire.com)